Janssen COVID-19 Vaccine can protect against variants of concern
Trial shows the single-shot Janssen COVID-19 Vaccine generates robust immune responses against several COVID-19 variants.
List view / Grid view
News
Cancer vaccine shows promise in glioblastoma trial
Personalised cancer vaccine increases progression free survival by approximately 50 percent in patients with newly diagnosed glioblastoma.
Sanaria® PfSPZ-CVac vaccine 75 percent effective at preventing malaria
Clinical studies optimising immunisation with Sanaria’s PfSPZ-CVac vaccine resulted in 77 and 75 percent of participants being protected from malaria infection.
Novel microfluidic device could enhance crystalline drug safety
The continuous-flow microfluidic device allows scientists to assess crystalline API growth rates, shapes and structures to more quickly identify the best conditions for drug manufacturing.
EMA to assess whether COVID-19 Vaccine Moderna can be used in adolescents
The European Medicines Agency (EMA) has begun evaluating whether to extend the use of the COVID-19 Vaccine Moderna to include adolescents aged 12 to 17.
Experts call for improved oversight to combat rise of unproven stem cell therapies
Stem cell therapy authorities urge the WHO to create an advisory committee for regenerative medicine and work to combat the rising use of unproven stem cell therapies worldwide.
Alzheimer’s drug Aduhelm™ authorised in US under accelerated approval
Aduhelm™ (aducanumab-avwa) is the first new treatment approved for Alzheimer’s since 2003 and the first therapy to target the fundamental pathophysiology of the disease – amyloid plaques.
Imfinzi increases five year survival to 43 percent in Stage III lung cancer trial
New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five year survival rate of over 40 percent in patients with Stage III non-small cell lung cancer.
![MIT chemical engineers have devised a new way to formulate hydrophobic drugs by turning them into a nanoemulsion, which can be poured into a mold and dried into tablets. The nanoemulsion can also be used to form small particles, seen in the vials [Credit: Felice Frankel].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MIT-HYDROPHOBIC-DRUGS-nanoemulsion-300x278.jpg)
![MIT chemical engineers have devised a new way to formulate hydrophobic drugs by turning them into a nanoemulsion, which can be poured into a mold and dried into tablets. The nanoemulsion can also be used to form small particles, seen in the vials [Credit: Felice Frankel].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MIT-HYDROPHOBIC-DRUGS-nanoemulsion-e1623151984970.jpg)
Thermogelling nanoemulsion enhances drug loading of hydrophobic APIs
Using a new formulation technique, researchers were able to more than double drug loading of a hydrophobic active pharmaceutical ingredient in tablets. Thus, the new formulation method may lead to smaller pills delivering the same therapeutic benefit.
Chemotherapy-free combination shows potential in lymphocytic leukaemia trial
Imbruvica® (ibrutinib) plus Venclexta®/Venclyxto® (venetoclax) resulted in 95 percent of chronic lymphocytic leukaemia patients surviving without disease progression for two years.
Tremfya® improves psoriatic arthritis joint function and skin clearance
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
Pharma supply companies form the Alliance to Zero
The Alliance to Zero was founded by eight pharma/biotech supply companies to promote the transition of the pharma sector to net zero emissions.
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
EU regulators release medicine demand forecasting guidance for future crises
The new recommendations, developed in the context of the COVID-19 pandemic, are designed to help countries and other stakeholders forecast demand of medicines in future pandemics.
Lynparza® improves invasive disease-free survival in high-risk early breast cancer trial
In the Phase III OlympiA trial, Lynparza® (olaparib) reduced the risk of cancer recurrences or death by 42 percent in patients with BRCA-mutated high-risk early breast cancer.